Citigroup Boosts Establishment Labs (NASDAQ:ESTA) Price Target to $50.00

Establishment Labs (NASDAQ:ESTA) had its price objective increased by Citigroup from $45.00 to $50.00 in a research report released on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock.

Other analysts have also issued research reports about the company. Stephens restated an overweight rating and issued a $68.00 price objective on shares of Establishment Labs in a report on Wednesday, August 7th. Mizuho raised their price objective on shares of Establishment Labs from $65.00 to $70.00 and gave the company a buy rating in a research report on Thursday, June 6th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Establishment Labs from $61.00 to $50.00 and set an overweight rating on the stock in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Establishment Labs has an average rating of Moderate Buy and a consensus target price of $57.60.

Establishment Labs Stock Down 6.4 %

Establishment Labs stock opened at $41.82 on Tuesday. Establishment Labs has a 52 week low of $16.96 and a 52 week high of $60.12. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -13.32 and a beta of 1.20. The company’s 50-day moving average price is $42.81 and its two-hundred day moving average price is $47.19. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The company had revenue of $44.12 million for the quarter, compared to analyst estimates of $43.10 million. Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. Establishment Labs’s revenue was down 9.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.65) EPS. On average, analysts expect that Establishment Labs will post -2.2 EPS for the current fiscal year.

Insider Transactions at Establishment Labs

In related news, CEO Quiros Juan Jose Chacon sold 3,866 shares of the stock in a transaction on Monday, July 8th. The stock was sold at an average price of $45.01, for a total value of $174,008.66. Following the completion of the transaction, the chief executive officer now owns 215,030 shares in the company, valued at approximately $9,678,500.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 11.44% of the stock is owned by insiders.

Hedge Funds Weigh In On Establishment Labs

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ESTA. Mudita Advisors LLP boosted its position in shares of Establishment Labs by 49.7% in the fourth quarter. Mudita Advisors LLP now owns 142,400 shares of the company’s stock worth $3,687,000 after buying an additional 47,284 shares during the period. Stableford Capital II LLC acquired a new position in shares of Establishment Labs in the 1st quarter valued at about $1,568,000. BNP Paribas Financial Markets lifted its position in shares of Establishment Labs by 32,968.7% in the first quarter. BNP Paribas Financial Markets now owns 97,222 shares of the company’s stock worth $4,949,000 after purchasing an additional 96,928 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Establishment Labs by 13.6% during the first quarter. Swiss National Bank now owns 37,500 shares of the company’s stock worth $1,909,000 after purchasing an additional 4,500 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new position in Establishment Labs during the first quarter valued at approximately $263,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.